Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Hetlioz
Tasimelteon is a melatonin receptor agonist used to treat non-24-hour sleep-wake disorder (Non-24). It selectively binds to MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus (SCN), the body's master clock, helping to regulate the circadian rhythm. It is classified as a hypnotic.
For the treatment of Non-24-Hour Sleep-Wake Disorder in totally blind individuals.
Outcome:
Increased tasimelteon levels, leading to increased side effects.
Mechanism:
Fluvoxamine inhibits CYP1A2, the enzyme responsible for tasimelteon metabolism.
Outcome:
May increase tasimelteon levels.
Mechanism:
Cimetidine inhibits CYP1A2.
Outcome:
Minor interaction, no clinically significant effects expected.
Mechanism:
Both drugs are metabolized by the liver, but through different pathways.
Most likely new formulation: Extended-release formulation (Year: 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a low probability of significant regulatory changes in the next 2 years (less than 10% likelihood).
Hypnotic, Melatonin Receptor Agonist
Melatonin Analog